source
- GSK receives FDA approval for ROS1 inhibitor Jideytro, marking its first lung cancer drugGSK's FDA approval of Jideytro, a ROS1 inhibitor for advanced non-small cell lung cancer patients with ROS1 gene fusions who have already received ROS1-directed therapy, was announced on Wednesday.…
- FDA advisory panel backs broader use of wellness peptide BPC-157 despite internal concernsThe FDA advisory committee voted Thursday to recommend loosening restrictions on BPC-157, a peptide popular among health and wellness enthusiasts for muscle repair, injury healing, metabolism suppo…